The tyrosine kinase inhibitor dasatinib suppresses cytokine production by plasmacytoid dendritic cells by targeting endosomal transport of CpG DNA

Plasmacytoid dendritic cells (pDCs) produce a vast amount of interferon (IFN)‐α in response to nucleic acids from viruses and damaged self‐cells through Toll‐like receptor (TLR)7 and TLR9. Pharmaceutical agents that suppress IFN‐α production by pDCs are instrumental in elucidating the mechanisms behind IFN‐α production, and in developing novel therapies for inflammatory disorders that involve pDCs. Here, we show that a tyrosine kinase inhibitor for chronic myeloid leukemia with multiple targets, dasatinib, strongly suppresses production of IFN‐α and proinflammatory cytokines by human pDCs stimulated with multimeric CpG oligodeoxynucleotides (CpG‐A) without reducing viability. In contrast, other tyrosine kinase inhibitors, imatinib, and nilotinib, did not suppress the cytokine production at clinically relevant concentrations. Inhibitors of SRC family kinases (SFKs), which are prominent targets of dasatinib, also suppressed the cytokine production. Notably, however, dasatinib, but not SFK inhibitors, abrogated prolonged localization of CpG‐A in early endosomes, which is a critical step for pDCs to produce a large amount of IFN‐α. This study suggests that dasatinib suppresses IFN‐α production by pDCs by inhibiting SFK‐dependent pathways and SFK‐independent endosomal retention of CpG DNA. Kinases controlling the distinctive endosomal trafficking in pDCs may be exploited as targets to develop novel therapies for pDC‐related inflammatory disorders.     

Self‐priming determines high type I IFN production by plasmacytoid dendritic cells

Plasmacytoid dendritic cells (pDCs) are responsible for the robust and immediate production of type I IFNs during viral infection. pDCs employ TLR7 and TLR9 to detect RNA and CpG motifs present in microbial genomes. CpG‐A was the first synthetic stimulus available that induced large amounts of IFN‐α (type I IFN) in pDCs. CpG‐B, however, only weakly activates pDCs to produce IFN‐α. Here, we demonstrate that differences in the kinetics of TLR9 activation in human pDCs are essential for the understanding of the functional difference between CpG‐A and CpG‐B. While CpG‐B quickly induces IFN‐α production in pDCs, CpG‐A stimulation results in delayed yet maximal IFN‐α induction. Constitutive production of low levels of type I IFN in pDCs, acting in a paracrine and autocrine fashion, turned out to be the key mechanism responsible for this phenomenon. At high cell density, pDC‐derived, constitutive type I IFN production primes pDCs for maximal TLR responsiveness. This accounts for the high activity of higher structured TLR agonists that trigger type I IFN production in a delayed fashion. Altogether, these data demonstrate that high type I IFN production by pDCs cannot be simply ascribed to cell‐autonomous mechanisms, yet critically depends on the local immune context.     

Innate immune responses to human rotavirus in the neonatal gnotobiotic piglet disease model

Intestinal and systemic dendritic cell (DC) frequencies, serum and small intestinal content cytokines and uptake/binding of human rotavirus (HRV) virus‐like particles (VLP) were studied in HRV acutely infected or mock‐inoculated neonatal gnotobiotic piglets. Intestinal, mesenteric lymph node (MLN) and splenic plasmacytoid DCs (pDCs), conventional DCs (cDCs) and macrophages/monocytes were assessed by flow cytometry. In infected pigs, serum and small intestinal content interferon‐α (IFN‐α) were highest, interleukin‐12 (IL‐12) was lower and IL‐10, tumour necrosis factor‐α and IL‐6 were minimal. Compared with mock‐inoculated piglets, frequencies of total intestinal DCs were higher; splenic and MLN DC frequencies were lower. Most intestinal pDCs, but few cDCs, were IFN‐α⁺ and intestinal macrophages/monocytes were negative for IFN‐α. Serum IFN‐α levels and IFN‐α⁺ intestinal pDCs were highly correlated, suggesting IFN‐α production in vivo by intestinal pDCs (r = 0·8; P < 0·01). The intestinal pDCs and cDCs, but not intestinal macrophages/monocytes, of HRV‐infected piglets showed significantly lower VLP uptake/binding compared with mock‐inoculated piglets, suggesting higher activation of pDCs and cDCs in infected piglets. Both intestinal pDCs and cDCs were activated (IFN‐α⁺ and lower VLP binding) after HRV infection, suggesting their role in induction of HRV‐specific immunity. Dose‐effects of HRV on serum IFN‐α and IFN‐α⁺ DCs were studied by infecting piglets with 100‐fold higher HRV dose. A high dose increased parameters associated with inflammation (diarrhoea, intestinal pathology) but serum IFN‐α and IFN‐α⁺ DCs were similar between both groups. The pDCs have both anti‐ and pro‐inflammatory functions. Stimulation of the anti‐inflammatory effects of pDCs after the high dose, without increasing their pro‐inflammatory impacts, may be critical to reduce further immunopathology during HRV infection.     

Sequence independent interferon‐α induction by multimerized phosphodiester DNA depends on spatial regulation of Toll‐like receptor‐9 activation in plasmacytoid dendritic cells

Single‐stranded versus multimeric phosphorothioate‐modified CpG oligodeoxynucleotides (ODNs) undergo differential endosomal trafficking upon uptake into plasmacytoid dendritic cells (pDCs), correlating with Toll‐like receptor‐9‐dependent pDC maturation/activation (single‐stranded B‐type CpG ODN) or interferon‐α (IFN‐α) induction (multimeric A‐type CpG ODN), respectively. As was recently shown, IFN‐α production, other than by CpG ODNs, can also be induced in a sequence‐independent manner by phosphodiester (PD) ODNs multimerized by 3′ poly‐guanosine (poly‐G) tails. We investigate here the type of endosomal trafficking responsible for IFN‐α induction by natural PD ODN ligands. We show that 3′ extension with poly‐G tails leads to multimerization of single‐stranded PD ODNs and to enhanced cellular uptake into pDCs. While monomeric PD ODNs, which induce CpG‐dependent Toll‐like receptor‐9 stimulation and pDC maturation/activation, localized to late endosomal/lysosomal compartments, the poly‐G multimerized PD ODNs, which induce CpG‐independent IFN‐α production, located to vesicles with a distinct, ‘early’ endosomal phenotype. We conclude that poly‐G‐mediated multimerization of natural PD ODNs allows for sequence‐independent, Toll‐like receptor‐9‐dependent IFN‐α induction in pDCs by combining three distinct effects: relative protection of sensitive PD ODNs from extracellular and intracellular DNase degradation, enhanced cellular uptake and preferential early endosomal compartmentation.     

Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self‐DNA

Psoriasis is a T‐cell‐mediated skin autoimmune disease characterized by the aberrant activation of dermal dendritic cells (DCs) and the sustained epidermal expression of antimicrobial peptides. We have previously identified a link between these two events by showing that the cathelicidin antimicrobial peptide LL37 has the ability to trigger self‐nucleic acid mediated activation of plasmacytoid DCs (pDCs) in psoriatic skin. Whether other cationic antimicrobial peptides exert similar activities is unknown. By analyzing heparin‐binding HPLC fractions of psoriatic scales, we found that human beta‐defensin (hBD)2, hBD3, and lysozyme are additional triggers of pDC activation in psoriatic skin lesions. Like LL37, hBD2, hBD3, and lysozyme are able to condense self‐DNA into particles that are endocytosed by pDCs, leading to activation of TLR9. In contrast, other antimicrobial peptides expressed in psoriatic skin including elafin, hBD1, and psoriasin (S100A7) did not show similar activities. hBD2, hBD3, and lysozyme were detected in psoriatic skin lesions in the vicinity of pDCs and found to cooperate with LL37 to induce high levels of IFN production by pDCs, suggesting their concerted role in the pathogenesis of psoriasis.     

Human plasmacytoid dendritic cells elicit a Type I Interferon response by sensing DNA via the cGAS‐STING signaling pathway

Plasmacytoid dendritic cells (pDCs) are a major source of type I interferon (IFN) and are important for host defense by sensing microbial DNA via TLR9. pDCs also play a critical role in the pathogenesis of IFN‐driven autoimmune diseases. Yet, this autoimmune reaction is caused by the recognition of self‐DNA and has been linked to TLR9‐independent pathways. Increasing evidence suggests that the cytosolic DNA receptor cyclic GMP‐AMP (cGAMP) synthase (cGAS) is a critical component in the detection of pathogens and contributes to autoimmune diseases. It has been shown that binding of DNA to cGAS results in the synthesis of cGAMP and the subsequent activation of the stimulator of interferon genes (STING) adaptor to induce IFNs. Our results show that the cGAS‐STING pathway is expressed and activated in human pDCs by cytosolic DNA leading to a robust type I IFN response. Direct activation of STING by cyclic dinucleotides including cGAMP also activated pDCs and knockdown of STING abolished this IFN response. These results suggest that pDCs sense cytosolic DNA and cyclic dinucleotides via the cGAS‐STING pathway and that targeting this pathway could be of therapeutic interest.     

Interferon‐α coincides with suppressed levels of pentraxin‐3 (PTX3) in systemic lupus erythematosus and regulates leucocyte PTX3 in vitro

Dysfunctional elimination of cell debris, and the role of opsonins such as pentraxins, is of interest regarding systemic lupus erythematosus (SLE) pathogenesis. Interferon (IFN)‐α is typically elevated during SLE flares, and inhibits hepatocyte production of the pentraxin ‘C‐reactive protein’ (CRP), partly explaining the poor correlation between CRP levels and SLE disease activity. The extrahepatically produced ‘pentraxin 3’ (PTX3) shares waste disposal functions with CRP, but has not been studied extensively in SLE. We analysed serum PTX3 in SLE, and assessed its interference with IFN‐α in vitro. Serum samples from 243 patients with SLE and 100 blood donors were analysed regarding PTX3. Patient sera were analysed for IFN‐α, and genotyped for three PTX3 single nucleotide polymorphisms reported previously to associate with PTX3 levels. Stimulated PTX3 release was assessed in the presence or absence of IFN‐α in blood donor neutrophils and peripheral blood mononuclear cells (PBMC). Serum PTX3 was 44% lower in patients with SLE compared to blood donors (P < 0·0001) and correlated with leucocyte variables. Patients with undetectable IFN‐α had 29% higher median PTX3 level than patients with detectable IFN‐α (P = 0·01). PTX3 production by PBMC was inhibited by IFN‐α, whereas neutrophil degranulation of PTX3 was increased. No differences in PTX3 levels were observed between the SNPs. In conclusion, median serum PTX3 is lower in SLE (especially when IFN‐α is detectable) compared to blood donors. In addition to its potential consumption during waste disposal, it is plausible that IFN‐α also attenuates PTX3 by inhibiting synthesis by PBMC and/or exhausting PTX3 storage in neutrophil granules.     

Sca‐1 expression defines developmental stages of mouse pDCs that show functional heterogeneity in the endosomal but not lysosomal TLR9 response

Plasmacytoid dendritic cells (pDCs) play an important role in innate and adaptive immunity and were shown to be identical to previously described natural interferon (IFN)‐α‐producing cells. Here, we describe two functionally distinct pDC subpopulations that are characterized by the differential expression of stem cell antigen‐1 (Sca‐1; Ly‐6A/E). Sca‐1^? pDCs are mainly found in the BM, appear first during development, show a higher proliferative activity, and represent the more precursor phenotype. Sca‐1⁺ pDCs are mostly located in secondary lymphoid organs and represent a later developmental stage. Sca‐1^? pDCs give rise to an Sca‐1⁺ subset upon activation or in response to endogenous type I IFN. Interestingly, in contrast to Sca‐1^? pDCs, Sca‐1⁺ pDCs are defective in IFN‐α production upon endosomal TLR9 stimulation, whereas lysosomal signaling via TLR9 is functional in both subsets. Gene expression analysis revealed that osteopontin is strongly upregulated in Sca‐1^? pDCs. These data provide evidence for the molecular basis of the observed functional heterogeneity, as the intracellular isoform of osteopontin couples TLR9 signaling to IFN‐α expression. Taken together, our results indicate that Sca‐1^? pDCs are an early developmental stage of pDCs with distinct innate functions representing the true murine natural IFN‐α‐producing cells.     

IRF‐5 and NF‐κB p50 co‐regulate IFN‐β and IL‐6 expression in TLR9‐stimulated human plasmacytoid dendritic cells

Synthetic oligonucleotides (ODN) expressing CpG motifs mimic the ability of bacterial DNA to trigger the innate immune system via TLR9. Plasmacytoid dendritic cells (pDCs) make a critical contribution to the ensuing immune response. This work examines the induction of antiviral (IFN‐β) and pro‐inflammatory (IL‐6) cytokines by CpG‐stimulated human pDCs and the human CAL‐1 pDC cell line. Results show that interferon regulatory factor‐5 (IRF‐5) and NF‐κB p50 are key co‐regulators of IFN‐β and IL‐6 expression following TLR9‐mediated activation of human pDCs. The nuclear accumulation of IRF‐1 was also observed, but this was a late event that was dependant on type 1 IFN and unrelated to the initiation of gene expression. IRF‐8 was identified as a novel negative regulator of gene activation in CpG‐stimulated pDCs. As variants of IRF‐5 and IRF‐8 were recently found to correlate with susceptibility to certain autoimmune diseases, these findings are relevant to our understanding of the pharmacologic effects of “K” ODN and the role of TLR9 ligation under physiologic, pathologic, and therapeutic conditions.     

Interferon-�� and interleukin-12 are induced, respectively, by double-stranded DNA and single-stranded RNA in human myeloid dendritic cells

Dendritic cells (DCs) are initiators of innate immunity and acquired immunity as cells linking these two bio‐defence systems through the production of cytokines such as interferon‐α (IFN‐α) and interleukin‐12 (IL‐12). Nucleic acids such as DNA from damaged cells or pathogens are important activators not only for anti‐microbial innate immune responses but also in the pathogenesis of IFN‐related autoimmune diseases. Plasmacytoid DCs are regarded as the main effectors for the DNA‐mediated innate immunity by possessing DNA‐sensing toll‐like receptor 9 (TLR9). We here found that double‐stranded DNA (dsDNA) complexed with lipotransfectants triggered activation of human monocyte‐derived DCs (moDCs), leading to the preferential production of IFN‐α but not IL‐12. This indicates that myeloid DCs also function as supportive effectors against the invasion of pathogenic microbes through the DNA‐mediated activation in innate immunity. The dsDNA with lipotransfectants can be taken up by moDCs without co‐localization of endosomal LAMP1 staining, and the dsDNA‐mediated IFN‐α production was not impaired by chloroquine. These findings indicate that moDC activation by dsDNA does not involve the endosomal TLR pathway. In contrast, single‐stranded RNA (ssRNA) stimulated moDCs to secrete IL‐12 but not IFN‐α. This process was inhibited by chloroquine, suggesting an involvement of the TLR pathway in ssRNA‐mediated moDC activation. As might be inferred from our findings, myeloid DCs may function as a traffic control between innate immunity via IFN‐α production and acquired immunity via IL‐12 production, depending on the type of nucleic acids. Our results provide a new insight into the biological action of myeloid DCs underlying the DNA‐mediated activation of protective or pathogenic immunity.     

Human blood dendritic cells from allergic subjects have impaired capacity to produce interferon-α via toll-like receptor 9

Background High‐affinity IgE receptor (Fc?RI) expression on blood dendritic cells reportedly correlates with serum IgE levels. Our studies demonstrate that plasmacytoid dendritic cells (pDCs) secrete pro‐inflammatory cytokines (IL‐6, TNF‐α) following Fc?RI stimulation – a mode of activation that simultaneously reduces expression of Toll‐like receptor 9 (TLR9). Whether or not TLR9 and/or Fc?RI levels and their function on dendritic cells relate to allergic status is unknown. Objective The aim of this study is to compare the innate (TLR9‐mediated) immune response of human pDCs to TLR9 and Fc?RIα receptor expression in allergic and non‐allergic subjects. Methods Basophil‐depleted mononuclear cell fractions containing pDCs were prepared from peripheral blood of allergic and non‐allergic subjects. Intracellular TLR9 and surface Fc?RIα expression in blood dendritic cell antigen‐2‐positive cells were determined by flow cytometry. Activating anti‐IgE antibody, anti‐Fc?RIα antibody, and TLR9 agonist were used to stimulate cell suspensions, with cytokine levels determined by ELISA. Results No difference in the frequency of pDCs was detected among allergic (n=9) vs. non‐allergic (n=11) subjects (P=0.261). While there was also no difference in the baseline expression of TLR9, pDCs from allergic subjects produced sixfold less IFN‐α when stimulated with CpG (P=0.002). Conversely, there was higher Fc?RIα expression (P=0.01) on the pDCs of allergic subjects. Conclusions Impaired TLR9‐dependent immune responses in human pDCs are associated with allergic status and inversely correlated with Fc?RIα expression. This impaired innate immune response among dendritic cells of allergic subjects may lead to more targeted therapeutic approaches and could provide a better understanding of the mechanisms underlying conventional and CpG‐based immunotherapy.     

STS‐1 promotes IFN‐α induced autophagy by activating the JAK1‐STAT1 signaling pathway in B cells

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the overexpression of IFN‐α. IFN‐α induces autophagy via the JAK1‐STAT1 signaling pathway, contributing to the pathogenesis of SLE. Recent studies reported that B cells from patients with SLE and NZB/W F1 mice had enhanced autophagy activity; however, the mechanism still remains unknown. Here, we show that the protein tyrosine phosphatase STS‐1 (suppressor of T‐cell receptor signaling 1) was significantly overexpressed in B cells from patients with SLE and MRL/lpr mice. Notably, STS‐1 promoted IFN‐α‐induced autophagy in B cells by enhancing the JAK1‐STAT1 signaling activation. STS‐1 inhibited the phosphorylation of the E3 ubiquitin protein ligase c‐cbl, and subsequently promoted IFN‐α‐induced phosphorylation of tyrosine kinase 2, leading to JAK1‐STAT1 signaling activation. Furthermore, STAT1 and JAK1 inhibitors blocked the IFN‐α‐induced autophagy promoted by STS‐1, indicating that STS‐1 promotes IFN‐α‐induced autophagy via the JAK1‐STAT1 signaling. Our results demonstrate the importance of STS‐1 in regulating IFN‐α‐induced autophagy in B cells, and this could be used as a therapeutic approach to treat SLE.     

BST2/Tetherin is constitutively expressed on human thymocytes with the phenotype and function of Treg cells

In contrast to peripheral plasmacytoid DCs (pDCs), thymic pDCs constitutively express low levels of IFN‐α. This leads to induction of interferon secondary genes (ISGs) in medullary thymocytes, raising the question whether IFN‐α may play a role in T‐cell development. When characterizing further differences between peripheral and thymic pDCs, we found that thymic pDCs have a phenotype consistent with an “activated signature” including expression of TNF‐α and bone marrow stromal cell antigen 2 (BST2), but no expression of ILT7. Given that BST2 is induced by IFN‐α, and IFN‐α secretion is controlled by interaction between ILT7 and BST2, this regulatory pathway is apparently lost in thymic pDCs. Further, we also show that BST2 is constitutively expressed on a subset of medullary thymocytes at the mRNA and protein level reflecting a history of IFN‐α transduced signals. The majority of BST2⁺ thymocytes express CCR5 rendering them prevalent targets for R5‐tropic HIV infection. Moreover, BST2⁺ thymocytes express Foxp3 and CD25, consistent with the phenotype of natural Treg cells, and exert suppressive activity as they impair the proliferation of autologous CD3⁺ thymocytes. Collectively, our results suggest that low levels of IFN‐α secreted by thymic pDCs play an important role in the development of natural Treg cells.     

CCK8 negatively regulates the TLR9‐induced activation of human peripheral blood pDCs by targeting TRAF6 signaling

Plasmacytoid dendritic cells (pDCs) are specialized in rapid and massive secretion of type I interferon in response to foreign nuclei acids. Combined with their antigen presentation capacity, this powerful functionality enables pDCs to orchestrate innate and adaptive immune responses. Cholecystokinin octapeptide (CCK8) is a potent immunomodulator, whose role in pDCs function is unknown. In this study, we found that two different cholecystokinin receptors, CCK1R and CCK2R, are expressed on human peripheral blood pDCs. Exogenous CCK8 was able to modulate the TLR‐induced activation of pDCs, including phenotypic maturation, IFN‐α synthesis and secretion, and could also regulate the potential of pDCs to induce adaptive immune responses in vitro. CCK8 inhibited TLR9‐induced activation of tumor‐necrosis factor receptor‐associated factor 6, which is an important adapter protein in activation of interferon‐regulatory factor (IRF)5 and IRF7, possibly through CCK2R, by evoking the activity of protein kinase (PK)A and reducing the activity of PKC. All these results indicate that CCK8 can inhibit the TLR9‐induced phenotypic maturation and activation of pDCs, acting through CCK2R by modulating the tumor‐necrosis factor receptor‐associated factor 6 signaling pathways.     

TLR‐mediated STAT3 and ERK activation controls IL‐10 secretion by human B cells

IL‐10‐producing B cells have a regulatory effect in various mouse models for immune‐mediated disorders via secretion of IL‐10, a potent immunoregulatory cytokine. However, currently, the signaling pathways that regulate IL‐10 production in B cells are not well understood. Here, we show that TLR signaling, but not BCR activation or CD40 ligation, induces potent production of IL‐10 in human B cells. We demonstrate that the activation of STAT3 and ERK is required for TLR‐induced IL‐10 production by B cells, since inhibition of STAT3 or ERK activation abrogates TLR‐induced IL‐10 production. We also uncover a novel function of the TLR‐MyD88‐STAT3 pathway in B cells, namely controlling IL‐10 production, in addition to the known role for this pathway in antibody production. Furthermore, IFN‐α, a member of the type I IFN family, differentially modulates TLR7/8‐ and TLR9‐activated STAT3 and ERK in B cells, which provides an explanation for our findings that IFN‐α enhances TLR7/8‐induced, but not TLR9‐induced IL‐10 production. These results yield insights into the mechanisms by which TLR signaling regulates IL‐10 production in B cells and how type I IFN modulates TLR‐mediated IL‐10 production by B cells, therefore providing potential targets to modulate the function of IL‐10‐producing B cells.     

Endosomal Toll-like receptors in clinically overt and silent autoimmunity

Toll-like receptors (TLRs), first identified as pattern recognition receptors, are now recognized to serve as a key interface between innate and adaptive immunity. Systemic lupus erythematosus (SLE) is characterized by both continuous and cyclic stimulation of the innate and adaptive immune system by endogenous nucleic acids released from apoptotic or necrotic cells. TLR7 and TLR9 function as innate sensors of viral infection as their ligands are ssRNA and dsDNA, respectively. Recognition of self nucleic acids by endosomal TLRs in B cells and pDCs is thought to be an important step in the pathogenesis of SLE, generating anti-nuclear antibodies and producing type I IFN. In this review, we take a specific look at how TLR7, non-coding RNA, and SSA/Ro60 can contribute to clinical autoimmunity and organ damage in the context of neonatal lupus (NL). Although 15 times less common than SLE, NL provides a unique opportunity to study two different aspects of autoimmunity: passively acquired tissue injury in a developing fetus and clinical progression of disease in an asymptomatic mother found to have anti-Ro60 autoantibodies only after identification of heart block/rash in a child. Finally, we discuss hydroxychloroquine (HCQ) use by asymptomatic subjects which may forestall the clinical expression of autoimmunity.